Stocks-FATE-Fate Therapeutics Inc

FATE Fate Therapeutics Inc

6.65 0.28 (4.40%)
Delayed Prices By NASDAQ, in USD Market Open
Invest
Invest
0% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
618.98M
Day’s Range
6.52
-
6.77
52W Range
4.01
-
43.00
Volume (3M)
3.36M
Price-Earnings Ratio
-
Revenue
69.01M

Fate Therapeutics Inc Latest News

View All
Pinned Post
eToro Team
🎉 Here’s a little preview introducing 16 YEARS of INVESTING on eToro 😏🤑 With love, - The eToro Team youtu.be/UFYvpJxh2qA
Like CommentShare
Show more comments2 of 54
2 replies
null
.
Top Discussions
LordKingDayo
Spoke about 19 stocks in the ARKInvest $ARKG #Genomics ETF FUND... and I shared the best 4 to buy atm. I also spoke about $BNGO (BioNano Genomics Inc) at the end. $RXRX $QSI $CDXS (Codexis Inc) $REGN (Regeneron Pharmaceuticals) $BFLY (Butterfly Network Inc.) $NRIX $PRME $PFE (Pfizer) $GH (Guardant... Show More
Like CommentShare
null
.
Iurii Drabik
Stock markets dynamics this week on eToro (EU vs. US) The US market is much more volatile this week than the European. It's not a big surprise, but still, it's interesting to look at the numbers. Stocks price change in the last 5 days: US (top gainers): 1. +90% ($CVAC (CureVac NV)) 2. +72%... Show More
Like CommentShare
null
.
freeride2020
$FATE (Fate Therapeutics Inc) bullish ?
FATE
Fate Therapeutics Inc
6.65
0.28 (4.40%)
Trade
JulioBarrera123
Hola, acabo de abrir nuevas operaciones en $FATE (Fate Therapeutics Inc) y en $GALA , me gusta sentir que las acciones que tengo van en subida, y creo que subirían más en especial $GALA que a tenido un crecimiento enorme estos últimos días, bonito día para todos Translate
Like CommentShare
null
.
Cancer-Med
Dear Investors, Here is your monthly update for December 2022. ✨ Most financial markets stuck to the trend for 2022, ending the year with losses. China on the other hand managed to buck this trend after the Chinese government's decision to relax their zero-covid policies. 💭 Find out more about... Show More

About Fate Therapeutics Inc

Fate Therapeutics is an American biopharmaceutical company founded in 2007 and based in San Diego, California. The organisation specialises in the development of programmed cellular immunotherapies for cancer and immune disorders. It serves healthcare professionals across the USA, manufacturing a range of therapies based on their iPSC-derived cell product candidates. Fate Therapeutics bases their cellular immunotherapies on their novel ex vivo cell programming approach. The company started trading publicly on the NASDAQ GS in 2013, using the ticker FATE. In October 2020, the FATE price chart was showing a 52-week low of $12.59 and a 52-week high of $42.22, with a market cap of $3.3bn. The company does not expect to pay any cash or other dividend on its common stock. This innovative and specialist healthcare company collaborates with numerous respected partners, including Janssen Biotech, ONO Pharmaceutical Co., and the Masonic Cancer Centre at the University of Minnesota. These collaborations have led to advancements in the first-ever iPSC-derived cell therapy — FT500 — and the first-ever engineered iPSC-derived cell therapy — FT516. This resulted in the clinical development of these therapies in the United States. If you are interested in FATE stock, you can track this instrument by adding it to your eToro watchlist.
449
Employees
San Diego, California, US
HQ
2007
Founded
J. Scott Wolchko
CEO
Show More

Upcoming Earnings

27
FEB
REPORTS
Fate Therapeutics Inc Q4 2022 earnings report is expected to be released after market open

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
42
Very Low
Industry 
Avg. 45 
32
Environment
45
Social
47
Governance

People Also Bought